Dr. Leah @pyterlab.bsky.social is the 1st @osucccjames.bsky.social presenter at Great Lakes Breast Cancer Symposium 2025! Thanks @upmchillmancc.bsky.social for hosting!
Daniel Stover, MD, FASCO
@stoverlab.bsky.social
Breast cancer physician-scientist | Clinical computational oncology @OSUCCC_James | Vice Chair, @Alliance_org Breast Cmte | Views own | http://u.osu.edu/StoverLab & https://u.osu.edu/bctrp
Is liquid biopsy useful in bone-only metastatic #breastcancer? Surprise! ✅Pts w bone-only disease are just as likely to have detectable ctDNA ✅ctDNA tumor fraction remains prognostic in bone-only setting link.springer.com/article/10.1... @osucccjames.bsky.social
Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study - Breast Cancer Research and Treatment
Purpose Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequ...
link.springer.com
Could not be more thankful for and proud of my parents today ❤️💯
Think of scientific writing as eating a whale: it must be done one forkful at a time! rdcu.be/egxhh
An open letter to graduate students and other procrastinators: it’s time to write
Nature Biotechnology - An open letter to graduate students and other procrastinators: it’s time to write
rdcu.be
Thank you to @stolaney1.bsky.social @dfcibreastonc.bsky.social for inviting me to give the J. Dirk Iglehart, M.D. Visiting Scholar Lecture at the DF/HCC Breast & Gynecologic Cancer Symposium. Incredible science, great friends & connections - what an honor! www.dfhcc.harvard.edu/events/dfhcc...
Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...
New #JITC article: T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy jitc.bmj.com/content/13/2...
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoad...
Background Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferas...
jitc.bmj.com
Did you register for THE conference that covers breast cancer AND normal mammary gland development yet? The GRC Mammary Gland Biology and Neoplasia abstracts will be evaluated for short talks from trainees soon, so get your abstract in! www.grc.org/mammary-glan...
2025 Mammary Gland Biology Conference GRC
The 2025 Gordon Research Conference on Mammary Gland Biology will be held in Newry, Maine. Apply today to reserve your spot.
grc.org
Critical to keep shining light on the crucial issue of #financialToxicity & cancer care.
Fumiko Ladd Chino, MD FASCO@fumikochino.bsky.social · last yr."It's so heartbreaking when someone has to do a GoFundMe to pay for their medical care or to pay for their funeral or the funeral of a loved one." 🎙️ Our #financialToxicity @ascocancer.bsky.social podcast with Drs @stage4kelly.bsky.social & @ryannipp.bsky.social is out now! Listen today:
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement...
ascopubs.org
In Ohio during FY23 (2022-2023) this was the impact of NIH funding: $1.01 Billion in grants and contracts $2.05 Billion in economic support 13,061 jobs supported This reduction in NIH indirect will decimate research and limit health care advances www.unitedformedicalresearch.org/nih-in-your-...
NIH In Your State - United For Medical Research
Select a state on the map to see the impact of NIH funding across America.
unitedformedicalresearch.org
Oncologist burnout ⬆️14% over past 10yrs. ➡️Emotional exhaustion: 38% (2013) to 57% (2023) ➡️Top stressors: Staffing, EHR, payers ➡️Top fixes: ⬆️support, ⬇️workload ➡️What sparks joy? Talking w patients, helping pt QOL Oncologists just want time to help patients feel better. ascopubs.org/doi/pdf/10.1...
State of Professional Well-Being, Satisfaction, and Career Plans Among US Oncologists in 2023 | JCO Oncology Advances
PURPOSERecent data suggest that the rate of burnout among oncologists has risen over time. In addition to the negative effect of burnout on individuals, widespread burnout may prevent the oncology wor...
ascopubs.org
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...
breast-cancer-research.biomedcentral.com
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast 👉Who needs testing? 👉OLYMPIA updates 👉Concurrent PARPi use w/ other adj tx ascodaily.libsyn.com/advances-in-...
ASCO Daily News: Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations
Dr. Jessica Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive gen...
ascodaily.libsyn.com
Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social
Congratulations to so many fantastic individuals @drdonsdizon.bsky.social @drdawnhershman.bsky.social Susan Domchek, Ian Krop, and many others!
American Society of Clinical Oncology@ascocancer.bsky.social · 2y agoAlongside the Conquer Cancer Foundation we congratulate the recipients of our 2025 Special Awards! #ASCO25 Learn more: brnw.ch/21wQhFu
Fantastic USC Keck SOM Breast Cancer Symposium with great faculty, fellow cases, and new collaborations. Offering my support to all those here in LA impacted by the wildfire devastation.
@drjbhattacharya.bsky.social - Need your leadership to provide clarity & support to re-initiate #NIH #NCI communications, study sections, & meetings. Abrupt stop with no clear path forward causing confusion. Biomedical research is a critical engine of progress, health, and economic activity.
Kim Rathmell to step down as NCI Director January 20. Hope that we can benefit from her leadership at the NCI again in the future.
🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨 We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap! ascopubs.org/toc/op/21/1
JCO Oncology Practice: Vol 21, No 1
ascopubs.org
Thank you @ascocancer.bsky.social for devoting an entire issue of JCO OP to the topic of #FinancialToxicity and thank you to @fumikochino.bsky.social @ryannipp.bsky.social for inviting me to 🖊️ a piece for this, on my experience with financial toxicity as someone with privilege and savings.
Fumiko Ladd Chino, MD FASCO@fumikochino.bsky.social · 2y ago🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨 We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap! ascopubs.org/toc/op/21/1
If physician-scientists were 'in it for the money', we would probably choose different jobs . 🤔Incentives for research are 1) poorly delineated; 2) infrequently implemented; 3) lag clinical incentives many fold. 💰 is not the *only* incentive: research time, space, institutional support are valued
The American Society for Clinical Investigation@the-asci.org · 2y agoDecember's most engaging article by Eva Catenaccio et al. shows that prolonged physician-scientist training postpones full salary earnings compared with MD physicians & MD-PhD physicians have a lower lifetime earning potential than MD physicians... https://insight.jci.org/articles/view/183476
Welcome to Nerea Lopetegui-Lia to the @osuwexmed.bsky.social @osucccjames.bsky.social Breast Medical Oncology Team! Very excited to have her join us from @clevelandclinic.bsky.social and can't wait to see the impact she has on breast cancer field and individual patients!
We need to think more about how we engage with patients who donate samples for research studies. www.nytimes.com/2025/01/07/h...
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.
nytimes.com
What do we know about how the biology of mammary gland lactation and involution impact breast cancer risk? Building on work from Dr. Pepper Schedin & many others, new work in #BreastCancerResearch from Ramaswamy Lab @osucccjames.bsky.social link.springer.com/article/10.1...
Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models - Breast Cancer Research
Background Epidemiological studies associate an increase in breast cancer risk, particularly triple-negative breast cancer (TNBC), with lack of breastfeeding. This is more prevalent in African America...
link.springer.com
Patient satisfaction is important. But medicine involves tough topics & hard decisions. -Treating provider & restaurant reviews the same is a mistake. -Obsession over fractions of pct points in satisfaction is unequivocally negatively impacting provider burnout. www.doximity.com/newsfeed/ab5...
Online Reviews: A Growing Threat to Physician Morale and Patient Care
One of the naive missteps I took shortly after transitioning from trainee into an attending role was to sign up for Google to alert me whenever one...
doximity.com
Analysis of residual disease specimens is challenging - but a fascinating study pooling 4 HER2+ clinical trials! @oncoalert.bsky.social @tomaspascualmd.bsky.social www.sciencedirect.com/science/arti...
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)
In HER2+ early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) bi…
sciencedirect.com
I'm pleased to announce that the ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed and will fund a young prostate cancer investigator every year, in perpetuity. The First Felix Feng YIA recipient will be announced this spring and celebrated at ASCO's annual meeting.